Esopic-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the treatment of gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and functional dyspepsia. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic and antiemetic effects by enhancing gastric motility and facilitating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and abdominal discomfort. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The sustained-release (SR) formulation ensures prolonged therapeutic plasma levels, improving patient compliance and efficacy. Esopic-L Capsule SR is indicated for patients with symptomatic GERD, erosive esophagitis, and functional dyspepsia where both acid suppression and enhanced gastrointestinal motility are required. It should be administered under medical supervision, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with renal or hepatic impairment, and potential drug interactions should be monitored. Common adverse effects may include headache, dizziness, and mild gastrointestinal disturbances. This combination therapy offers a synergistic approach to managing complex upper gastrointestinal disorders.